Ask Warren

Dx & Vx

180400 · KOSDAQ · ₩180400 · DXVX

₩1,895▼ ₩1 (0.05%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −7.56%
Market cap
₩187B
Enterprise value
₩173B
P/E
—
P/B
2.3×
Dividend yield
0.0%
ROE
−30.6%
Net margin
−96.2%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−64.6% from the high

₩1,319Today: ₩1,851 – ₩1,939₩5,360

Returns

  • 1W−7.6%
  • 1M−18.7%
  • 3M−5.7%
  • 6M−59.5%
  • YTD−39.6%
  • 1Y−7.6%
Volume today
46,524
0.9× the 20-day average
Traded today
₩89M
Listed shares
98,429,432
EPS (12 months)
−₩256
Earnings yield −13.5%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

41Quiet
  • BuzzQuietBuzz 41 of 100 (50 is a normal day for this stock).
  • MomentumWeak-20.5% over the last month; the price is below its 20-day average.

Signals describe activity, not recommendations. Not financial advice.

Dx & Vx stock overview

Dx & Vx (DXVX, KRX: 180400) is listed on KOSDAQ, in the Engineering services sector. The company is a Korean bio-healthcare firm operating in medical diagnostics, healthcare, and new drug development. Its shares closed at ₩1,895 on Oct 28, 2026, down 0.05% on the day, giving it a market value of ₩187B.

Key facts

Market cap
₩187B
Sector
Engineering services
Latest price change
−0.05%
As of
Oct 28, 2026
Main business
The company is a Korean bio-healthcare firm operating in medical diagnostics, healthcare, and new drug development.

Quick answers about Dx & Vx

What does Dx & Vx do?
The company is a Korean bio-healthcare firm operating in medical diagnostics, healthcare, and new drug development. Its diagnostics business offers genome testing services and in-vitro diagnostic kits, reagents, and CDMO services. Its healthcare business sells microbiome-based nutritional supplements and pharmaceuticals in Korea and abroad, including China through a subsidiary established in 2023.
What is the market cap of Dx & Vx?
The market capitalisation of Dx & Vx was ₩187B at the close on Oct 28, 2026.
Who are the largest shareholders of Dx & Vx?
According to the latest official filings, the largest reported holders are Lim Jong-yoon (62.40%, as of Oct 12, 2026); Park Young-ok (8.14%, as of Dec 16, 2025); Kwon Gyu-chan (0.09%, as of Mar 27, 2025).
When is the next earnings report from Dx & Vx?
Korean companies rarely announce results dates in advance. Based on when Dx & Vx filed the same report in past years, its next 3q results is expected around Nov 14, 2026.

Company profile

The company is a Korean bio-healthcare firm operating in medical diagnostics, healthcare, and new drug development. Its diagnostics business offers genome testing services and in-vitro diagnostic kits, reagents, and CDMO services. Its healthcare business sells microbiome-based nutritional supplements and pharmaceuticals in Korea and abroad, including China through a subsidiary established in 2023. It also pursues drug development, including an immuno-oncology vaccine and a universal COVID-19 vaccine.

Written by AI from the company's latest annual report.

Korean name
DXVX
Sector
Engineering services
Themes
—
CEO
김영종
Founded
Jun 2001
Listed
Nov 2015
Listed shares
98,429,432
Fiscal year ends
Month 12
Website
www.dxvx.com

Similar companies

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: Dx & Vx / DXVX / 180400 / KRX:180400

Source: KRX statistical information